Zymeworks (ZYME) to Acquire Theravance Biopharma (TBPH) for $929M in All-Cash Transaction

Key Takeaways

• Zymeworks has entered into an agreement to purchase Theravance Biopharma in an all-cash transaction valued at $929 million at $17 per share
• Acquisition pricing represents a 3.6% decrease compared to Theravance’s previous closing price of $17.63
• Yupelri, Theravance’s sole commercialized product for COPD treatment approved by FDA, recorded $266.6 million in 2025 U.S. net revenue
• Premarket trading showed Theravance shares declining 2.8% while Zymeworks decreased 1.4%
• Transaction completion is anticipated during the latter half of 2026 and projected to boost Zymeworks’ earnings and cash generation

In a significant consolidation move, Zymeworks has reached a definitive agreement to purchase Theravance Biopharma through an all-cash transaction totaling $929 million, offering shareholders $17 per share — representing a 3.6% reduction from Theravance’s Friday closing value of $17.63.

Zymeworks Inc., ZYME

Investor sentiment reflected skepticism. During Monday’s premarket session, Theravance shares declined 2.8% to $17.14. Zymeworks experienced a 1.4% pullback.

The below-market pricing is atypical in merger and acquisition activity and clarifies the negative market reaction. Most buyout transactions include a premium above current trading levels.

Neverthstanding, the transaction does provide a 22% markup relative to Theravance’s March 3 valuation, immediately following the announcement of late-stage clinical trial disappointment for ampreloxetine — a therapy candidate targeting a rare medical condition.

The unsuccessful trial prompted Theravance to initiate a corporate reorganization, resulting in workforce reductions of approximately 50%. Subsequently, management commenced a strategic review process, including potential sale scenarios.

Monday’s announcement effectively concludes that strategic evaluation period.

Assets Acquired by Zymeworks

The centerpiece of this transaction is Yupelri, a nebulized once-daily medication for chronic obstructive pulmonary disease already available commercially. This represents Theravance’s only marketed pharmaceutical product.

Yupelri achieved $266.6 million in U.S. net revenue during 2025, reflecting 12% growth versus the prior year. First quarter 2026 U.S. net revenue reached $62.4 million, demonstrating 7% year-over-year expansion.

Theravance maintains a 35% net profit participation arrangement for Yupelri within the United States, where commercialization occurs through a partnership with Viatris. According to Zymeworks, these royalty streams and profit-sharing arrangements currently deliver approximately $60 million in annualized cash generation.

This acquisition represents a strategic pivot for Zymeworks — historically concentrated in oncology therapeutics — establishing presence in the respiratory disease sector alongside major pharmaceutical companies like GSK, AstraZeneca, and Boehringer Ingelheim.

Future of Ampreloxetine Program

The unsuccessful development candidate remains part of the transaction structure. Under deal terms, Theravance shareholders will obtain contingent value rights entitling them to 80% of net proceeds resulting from future licensing arrangements, asset sales, or alternative monetization transactions involving ampreloxetine during the next decade.

Zymeworks retains the remaining 20% interest and has indicated intentions to explore monetization opportunities for this asset.

Zymeworks management projects the acquisition will enhance earnings and cash flow generation following transaction completion, targeted for the second half of 2026.

Completion remains contingent upon regulatory clearance and approval from Theravance shareholders.

Yupelri’s first quarter 2026 U.S. net revenue performance of $62.4 million marked 7% advancement compared to the corresponding period in the previous year.